- source： CentryMed
- author： CentryMed
-
2025.07.23
Chicago, IL – CentryMed announced today that it will present clinical data from two studies at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, USA, from May 30 to June 3, 2025. The data will be shared via poster presentations.
SMET12 is a fully human bispecific antibody targeting EGFR on tumor cells and CD3 on T cells. Developed based on CentryMed's proprietary antibody screening library and bispecific antibody platform, it is the world's first intravenous EGFR×CD3 bispecific antibody and the first in China to receive clinical trial approval from the NMPA. SMET12 recruits and activates T cells to release cytokines, directly killing tumor cells with a low risk of cytokine release syndrome (CRS).
About DNV3:
DNV3 is a LAG-3 antibody developed from CentryMed's proprietary high-capacity IgM antibody library. Representing one of the most promising immune checkpoint inhibitors beyond PD-1/PD-L1, DNV3 was initially developed for autoimmune diseases. Preclinical and clinical data indicate its strong potential to reverse resistance to PD-1/PD-L1 inhibitors. DNV3 binds to LAG-3 on activated T cells, directly activating the LAG-3 pathway. This initiates LAG-3 signaling, inhibiting T cell activity, eliminating inflammatory responses, and ultimately normalizing inflammation and maintaining immune homeostasis.
About CMDE005:
CMDE005 is a recombinant human anti-EGFR×CD3 enzyme-controlled bispecific antibody developed using CentryMed's proprietary pro-BiTE platform. This drug candidate offers advantages including high expression yield during production, high stability, and a long half-life. It is intended for treating various EGFR-positive advanced solid tumors. CMDE005 received clinical trial approval from China's NMPA in September 2024 and IND clearance from the US FDA in April 2025. The drug is currently in Phase I clinical trials, with patient enrollment ongoing in the fifth dose cohort, placing its clinical progress among the global leaders for this class of therapeutics.